SR33805 oxalate
SR33805 oxalate is a potent Ca2+ channel antagonist, with EC50s of 4.1 nM and 33 nM in depolarized and polarized conditions, respectively. SR33805 oxalate blocks L-type but not T-type Ca2+ channels. SR33805 oxalate can be used for the research of acute or chronic failing hearts.
Nur für Forschungszwecke. Wir verkaufen nicht an Patienten.
- CAS. Nr.: 121346-33-6
- Formel: C34H42N2O9S
- Molecular Weight:654.77
-
Speicherung:
Please store the product under the recommended conditions in the Certificate of Analysis.
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biologische Aktivität
-
Chemical Information
- Protokoll
- Reinheit & Dokumentation
- Verweise
-
Help & FAQs
-
HY-14650
DHEASteroid Hormone -
HY-13434
IonomycinCalcium Ionophore -
HY-N6687
CalcimycinCation Ionophore -
HY-W009724
2-Aminoethyl diphenylborinateIP3R Inhibitor -
HY-13434A
Ionomycin calciumCalcium Ionophore -
HY-B0317
AmlodipineCalcium Channel Blocker -
HY-A0064
Verapamil hydrochlorideCalcium Channel Blocker -
HY-100831
YM-58483CRAC Channel/SOCE Blocker -
HY-103312
Xestospongin CIP3R Inhibitor -
HY-103306
RyanodineRyanodine Receptor Modulator -
HY-B0233
IsradipineL-type Calcium Channel Blocker -
HY-B0309
FelodipineCalcium Channel Antagonist
Alle Calcium Channel Isoform-spezifische Produkte anzeigen
More
Biologische Aktivität
Beschreibung
In Vitro
SR33805 (0.01-10 µM; 3 d) oxalate inhibits growth factor-induced proliferation of SMC (0.20
SR33805 (10 µM; 10 min) oxalate restores the myocardial infarction (MI)-altered cell shortening without affecting the Ca2+ transient amplitude[2].
SR33805 (10 µM) oxalate decreases the activity of recombinant PKA[2].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Cell Line:Smooth muscle cells (SMC).
-
Concentration:0.01, 0.1, 1, 10 µM.
-
Incubation Time:3 days.
-
Result:Inhibited in a dose-dependent manner FCS-, bFGF and PDGF-induced proliferation of porcine SMC with IC50s of 0.26±0.08, 0.46±0.1 and 0.20±0.04 µM, respectively.
In Vivo
SR33805 (5 mg/kg/day; p.o. for 38 d) significantly reduces intimal hyperplasia in pigs[3].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:Male Wistar rats (5 weeks) are subjected to coronary artery ligature[2].
-
Dosage:0.2, 2, 20 mg/kg.
-
Administration:A single i.p. injection.
-
Result:Increased significantly both end-systolic strain (ESS) and fractional shortening (FS) by about +38 and +26%, respectively at the dose of 20 mg/kg
Did not affect other contractile parameters.
Chemical Information
-
CAS. Nr. 121346-33-6
-
Molecular Weight 654.77
-
Formel C34H42N2O9S
-
SMILES
O=S(C1=CC=C(OCCCN(C)CCC2=CC=C(OC)C(OC)=C2)C=C1)(C(N3C)=C(C(C)C)C4=C3C=CC=C4)=O.O=C(O)C(O)=O
-
Versand
Room temperature in continental US; may vary elsewhere.
-
Speicherung
Please store the product under the recommended conditions in the Certificate of Analysis.
Reinheit & Dokumentation
Verweise
[1]. Romey G, et, al. Effects of two chemically related new Ca2+ channel antagonists, SR33557 (fantofarone) and SR33805, on the L-type cardiac channel. Eur J Pharmacol. 1994 Sep 22; 263(1-2): 101-5. [Content Brief]
[2]. Mou YA, et, al. Beneficial effects of SR33805 in failing myocardium. Cardiovasc Res. 2011 Aug 1; 91(3): 412-9. [Content Brief]
[3]. Hainaud P, et, al. The calcium inhibitor SR33805 reduces intimal formation following injury of the porcine carotid artery. Atherosclerosis. 2001 Feb 1; 154(2): 301-8. [Content Brief]
Calculators
Konzentration (Stammlösung) × Volumen (Stammlösung) = Konzentration (Ziellösung) × Volumen (Ziellösung)
SR33805 oxalate Related Classifications
HY-103313 Related Classifications
Powered by Bioz